Supplement to The effect of dapagliflozin on the rate of kidney function decline in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD trial

Heerspink et.al.

Content:

Supplementary figure 1: Comparison of the distributions of estimated eGFR slopes during the acute phase (Panel A) and the chronic treatment phase (Panel B) for the individual patients in the dapagliflozin and placebo groups. eGFR slopes were determined by within individual linear regression. Panel A shows a uniform shift in the eGFR changes from baseline to week 2 (acute phase) in the dapagliflozin compared to placebo group. Panel B shows a somewhat greater shift of the left-end of the distribution of the eGFR slopes from week 2 to end of treatment in the dapagliflozin group.

Supplementary figure 2: Comparison of the distributions of estimated eGFR slopes during the chronic treatment phase for individual patients in the dapagliflozin and placebo groups with type 2 diabetes (Panel A) and without type 2 diabetes (Panel B). eGFR slopes were determined by within individual linear regression. Panel A shows a uniform shift in the eGFR changes from baseline to week 2 (acute phase) in the dapagliflozin compared to placebo group. Panel B shows a somewhat greater shift of the left-end of the distribution of the eGFR slopes from week 2 to end of treatment in the dapagliflozin group.

Supplementary figure 3: Systolic (Panel A) and diastolic (Panel B) blood pressure over the study.
Supplementary figure 1: Comparison of the distributions of estimated eGFR slopes during the acute phase (Panel A) and the chronic treatment phase (Panel B) for the individual patients in the dapagliflozin and placebo groups. eGFR slopes were determined by within individual linear regression. Panel A shows a uniform shift in the eGFR changes from baseline to week 2 (acute phase) in the dapagliflozin compared to placebo group. Panel B shows a somewhat greater shift of the left-end of the distribution of the eGFR slopes from week 2 to end of treatment in the dapagliflozin group.

A: Histogram kernel density plot acute eGFR slope based on within individual regression

B: Histogram kernel density plot chronic eGFR slope based on within individual regression
Supplementary figure 2: Comparison of the distributions of estimated eGFR slopes during the chronic treatment phase for individual patients in the dapagliflozin and placebo groups with type 2 diabetes (Panel A) and without type 2 diabetes (Panel B). eGFR slopes were determined by within individual linear regression. Panel A shows a uniform shift in the eGFR changes from baseline to week 2 (acute phase) in the dapagliflozin compared to placebo group. Panel B shows a somewhat greater shift of the left-end of the distribution of the eGFR slopes from week 2 to end of treatment in the dapagliflozin group.

A: Histogram kernel density plot chronic eGFR slope based on within individual regression in patients with diabetes

B: Histogram kernel density plot chronic eGFR slope based on within individual regression in patients without diabetes
Supplementary figure 3. Systolic (Panel A) and diastolic (Panel B) blood pressure over the study